Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E2)

Antibody Details

Product Details

Reactivity Species

SARS-CoV-2

⋅

Virus

Host Species

Mouse

Expression Host

HEK-293

Immunogen

SARS-CoV-2 Nucleocapsid (N) Protein

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

Formulation

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.

Storage and Handling

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Ships Overnight on Blue Ice

RRID

AB_2893995

Applications and Recommended Usage?
Quality Tested by Leinco

ELISA

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Anti-SARS-CoV-2 Nucleocapsid, clone NP1-E2, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Furthermore, it is reported to bind to the RNA binding domain of the N protein.

Antigen Distribution

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

Background

Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)¹. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins². The N protein is a highly conserved 46 kDa protein that shares 90% homology with SARS-CoV³. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively^{4, 5}, forming a helical nucleocapsid structure within the viral envelope⁶. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways^{7, 8}. The N protein is abundantly expressed during infection, and antibodies^{3, 9} and memory T cells^{10, 11} targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays¹². The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses¹³.

Antigen Details

Protein

SARS-CoV-2 Nucleocapsid (N)

PubMed

SARS-CoV-2 Nucleocapsid (N)

NCBI Gene Bank ID

43740575

Research Area

COVID-19

.

Viral

References & Citations

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.

2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.

3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.

4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.

5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.

6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.

7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.

8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.

9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.

10. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.

11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.

12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.

13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.

Technical Protocols